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Transarterial chemoembolization is ineffective for
neuroendocrine tumors metastatic to the caudate
lobe: a single institution review
Lawrence A Shirley1*, Megan McNally2, Ravi Chokshi3, Natalie Jones4, Patrick Tassone5, Gregory Guy6,
Hooman Khabiri6, Carl Schmidt1, Manisha Shah7 and Mark Bloomston1
Abstract
Background: Caudate lobe liver metastases occur commonly in patients with neuroendocrine tumors. It is
unknown, however, how these lesions respond to regional therapy and how their presence impacts outcomes. We
reviewed our experience treating these lesions using transarterial chemoembolization (TACE).
Methods: We reviewed radiographic response to TACE in 86 patients with metastatic neuroendocrine tumors to
the liver. We determined the impact of caudate lesions on outcomes in comparison to the cohort of patients
without caudate lesions, as well as response of caudate lesions to TACE versus lesions elsewhere in the liver.
Results: Caudate lesions were identified in 45 (52%) patients. All patients had disease in other liver segments. Only
seven caudate lesions (12.3%) had a radiographic response to TACE, whereas 82% of lesions elsewhere in the liver
demonstrated a response. The presence or absence of a caudate lesion did not impact the overall radiographic
(82.2% vs. 82.9%), symptomatic (64.4% vs. 56.1%), or biochemical (97.6% vs. 88.9%) response to TACE (P > 0.1 for all).
However, median overall survival was reduced in those presenting with caudate lesions (87.1 vs. 45.6 months,
P = 0.031).
Conclusions: Metastatic neuroendocrine tumors to the caudate lobe respond poorly to TACE. Symptomatic or
threatening caudate lobe lesions should be considered for palliative resection in spite of additional inoperable liver
metastases.
Keywords: Neuroendocrine tumors, Liver metastases, Locoregional therapy, Interventional radiology
Background
Neuroendocrine tumors (NET) are often aggressive but
indolent malignancies, which clinically do not manifest
for years, even in the presence of extensive metastatic
disease. Liver metastases are the most common site of
distant spread and are the primary threat to life [1].
Given the inherent resistance of neuroendocrine tumors
to systemic chemotherapy and the predilection for liver
metastases, liver-directed therapies such as transarterial
chemoembolization (TACE) play an important role in
treatment [2-4].
The caudate lobe of the liver differs anatomically from
the other lobes, as it drains directly into the inferior
vena cava (IVC) through veins separate from the main
hepatic veins [5]. The right and left branches of the por-
tal vein as well as both branches of the hepatic arteries
may supply the caudate lobe. Likely due to this complex
blood supply, the caudate lobe usually is spared from
metastatic disease to the liver and often hypertrophies to
compensate for the loss of normal liver parenchyma.
Studies have shown that malignancies other than NET
metastasize to the caudate lobe between 4% and 8% of
the time [6-8]. A single institution experience with 150
patients showed that the most common indication to
undergo caudate hepatectomy was for metastatic colo-
rectal cancer followed by primary hepatic malignancies -
cholangiocarcinoma and hepatocellular carcinoma. [6].
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Despite the noted anatomical differences, neuroendo-
crine tumors commonly metastasize to the caudate lobe
[9]. The significance of these metastases is unknown, as
is the impact on outcomes and response to regional
therapy. We reviewed our institution’s experience with
TACE for these lesions to determine the effect of caud-
ate lesions as well as their response to TACE.
Methods
Between 1992 and 2008, TACE was undertaken in 198
patients with neuroendocrine tumor metastases to the
liver. Although pre-TACE imaging was undertaken in all
patients, a subset of 98 patients had pre-TACE liver im-
aging (MRI or CT scan) performed in our system and
available for this retrospective review. Two independent
surgical oncologists (MB and CS) reviewed the patients’
pre-TACE imaging studies to identify those with caudate
lobe metastases (CLM). Two groups were identified: 45
patients who presented with evidence of CLM and 41
with no caudate lobe metastases (NCLM). A third sub-
group (n = 12), those who developed caudate lesions
during the course of therapy, was excluded. Demograph-
ics, clinicopathologic characteristics, procedure-related
complications, symptomatic, radiographic, and biochemical
response to TACE as well as outcomes were compared be-
tween these two groups. The Ohio State University Institu-
tional Review Board approved this project.
Transarterial chemoembolization procedure
TACE was considered for inability to control typical car-
cinoid symptoms with octreotide therapy, liver tumor
progression, or liver tumor burden that would threaten
liver function if any progression occurred. Eligibility cri-
teria for TACE included a tissue diagnosis of well or
moderately differentiated neuroendocrine tumor, serum
bilirubin <3 mg/dL, serum creatinine of <2 mg/dL, nor-
mal coagulation profile, and platelet count >100,000/mL.
Although our institution initially preferred whole-liver
TACE, in the more recent cohort of patients, a sequen-
tial lobar approach was adapted [10]. For staged TACE,
the liver lobe with greater tumor burden was treated
first. Any subsequent TACE treatments were timed ac-
cording to the patient’s symptoms, response, and how
well the initial procedure was tolerated. All treatment
decisions were made in a multidisciplinary setting in-
cluding the treating surgical, medical, and interventional
oncologists.
On the morning of the procedure, the patients were
first placed on a continuous intravenous octreotide infu-
sion, which continued until the day after the TACE. Pa-
tients with carcinoid syndrome were also maintained on
octreotide in the outpatient setting before and after
TACE. Prophylactic broad-spectrum antibiotics were
routinely administered. All procedures were undertaken
in the angiography suite under conscious sedation. A
diagnostic visceral angiogram via the femoral artery was
done to review the anatomy and verify portal vein pa-
tency. After cannulating the hepatic artery of interest,
the chemoembolic agents were injected (doxorubicin
30 mg, mitomycin 30 mg, cisplatinum 50 mg, ioxaglate
sodium, and ethiodized oil 37%). Embolic particles were
then infused until arterial stasis was achieved. Patients
were then monitored in the hospital until able to tolerate
oral hydration and narcotics.
Response to TACE assessment
Radiographic, symptom, and biochemical responses to
TACE were assessed at 3- to 6-month intervals. CT or
MRI was used to assess radiographic response to TACE.
Radiographic response was determined by the attending
radiologist’s overall impression according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST)
criteria and loss of tumor enhancement consistent with
necrosis [11].
Subjective symptom response was assessed by review
of clinic charts based on patient and physician assessment.
Worsening of symptoms as described by the patient or
the need for higher doses of octreotide to control symp-
toms were considered progression of disease. Stable dis-
ease was defined as no change in symptoms after TACE.
Improvement in symptoms was considered partial re-
sponse. Complete response was defined as the complete
resolution of symptoms.
The biochemical response to TACE was assessed by
determination of plasma pancreastatin levels [12]. Pre-
procedure pancreastatin levels were used as baseline.
Post-TACE pancreastatin levels that decreased by 20%
or more were considered a partial response, while
normalization of a previously elevated pancreastatin
was considered a complete response. Any increase of
serum pancreastatin level after reaching a nadir was
considered progression of disease.
Statistics
Overall survival curves were constructed using the
Kaplan-Meier method, and comparisons were made
using log-rank analysis. Overall survival was determined
from the time of the first TACE until death from any
cause as determined by medical records or social secur-
ity death index (ssdi.rootsweb.ancestry.com). Of note, all
deaths in this cohort were attributed to primary disease.
Independent predictors of survival were determined by
multivariate analysis by using the Cox proportional haz-
ards model. Categorical data were compared using chi-
square or Fisher’s exact test, and continuous data were
compared by Mann-Whitney U or Student’s t test, where
appropriate. All P values were derived from two-tailed
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tests. All statistical analyses were completed using SPSS
v 17.0 software (SPSS, Inc., Chicago, IL, USA).
Results
Patients with CLM and those with NCLM had no signifi-
cant differences in terms of age, gender, and comorbidities
(Table 1). Commensurate with their age, significant co-
morbidities - including coronary artery disease, hyperten-
sion, and diabetes - were present in 31% of the patients in
the CLM group and in 44% in the NCLM group (P =NS).
Patients in both groups were as likely to present with car-
cinoid syndrome at the time of TACE. The primary tumor
was more likely to have been removed in the NCLM
group (66%) than in patients with CLM (38%) (P < 0.03).
Both groups were similar in percentage of patients with a
pancreatic primary tumor, percentage of patients with a
non-functional tumor at presentation, and tumor grade
(Table 1).
Hepatic tumor burden was greater in patients with
caudate lobe metastasis in terms of number of liver seg-
ments involved, estimated proportion of liver involve-
ment, and pre-TACE pancreastatin levels (Table 1). At
the time of TACE, all patients had radiographic evidence
of bilobar hepatic disease. Additionally, 62% of the entire
cohort had evidence of extrahepatic disease, which was
statistically similar between groups. Pre-TACE pan-
creastatin levels were abnormally elevated in 80 patients
(normal pancreastatin level <135 pg/ml). A similar per-
centage of patients in each group had an elevated pan-
creastatin level (87% vs. 85%).
A total of 112 TACE procedures were undertaken in
86 patients, with a mean of 1.2 (range 1 to 2) per pa-
tient. Patients with CLM were less likely to undergo
whole-liver TACE (26.7% vs. 56.1% of patients in the
NCLM cohort, P = 0.005). Twenty-two patients under-
went planned staged TACE procedures with only one
lobe of the liver being treated during each session. Ten
post-procedural complications occurred in the total co-
hort, resulting in two deaths, one in each group. Both
deaths were a result of liver failure leading to multisys-
tem organ failure in patients with heavy hepatic tumor
burden (that is, >75%). Complication rates were similar
between groups. Atrial fibrillation with rapid ventricular
response requiring medical therapy was the most com-
mon complication, occurring in four patients. Intrahepa-
tic abscess formation occurred in two patients that
required percutaneous drainage. Two patients developed
severe hypertension requiring continuous monitoring,
and one of these suffered a subarachnoid hemorrhage
from a ruptured aneurysm that required neurosurgical
intervention. Right upper quadrant pain, fatigue, transi-
ent rise in liver transaminases, and fevers after TACE
were not considered complications as they occur com-
monly after this procedure. The mean length of stay was
similar between groups (Table 2).
Radiographic, symptomatic, and biochemical response
to TACE was similar between groups as was duration of
response (Table 2). Thirty-eight patients in the CLM group
had post-TACE CT scans available for comparison. In this
group, 79% demonstrated stable disease or partial response
to TACE with eight showing progression of disease. In the
Table 1 Demographics and clinicopathologic characteristics of 86 patients
Variables Caudate lobe metastases (n = 45) Number of caudate lobe
metastases (n = 41)
P value
Mean age (range) 54.8 (29 to 85) 53.5 (28 to 75) 0.85
Gender M:F 17:28 20:21 0.29
Comorbidities 14 (31%) 18 (43.9%) 0.45
Carcinoid syndrome pre-TACE 38 (84.4%) 35 (85.4%) .92
Primary resected 17 (38%) 27 (65.8%) <0.03
Pancreas primary 10 (22%) 10 (24.4%) 0.096
Tumor non-functional at presentation 30 (65.9%) 20 (48.9%) 0.085
Tumor grade 0.795
1 36 (80%) 33 (80.5%)
2 4 (8.9%) 4 (9.8%)
3 2 (4.4%) 2 (4.9%)
Median pre-TACE pancreastatin level pg/ml (range) 12,856 (84 to 56,200) 5,985 (104 to 46,400) <0.03
Median number of liver segments with metastases (range) 8 (5 to 8) 5 (2 to 8) <0.05
Median (range) percentage of metastatic burden to liver 71.4% (30 to 95) 48.7% (5 to 95) <0.01
Presence of extrahepatic disease 32 (71%) 22 (54%) 0.24
Presence of lymph node metastases 9 (22%) 7 (15.6%) 0.489
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NCLM group, 39 had post-procedure radiographic im-
aging. Similar to those with CLM, 82% had stabilization or
regression of disease after TACE, while seven progressed.
In patients with CLM, only seven caudate lesions (15.5%)
responded to TACE. There was no significant difference
in the control of symptoms in either group following
TACE. Only one patient reported worsening of symptoms
following TACE. CT scan noted this patient, in the NCLM
group, to have progression of disease. As assessed by
changes in pancreastatin level, there was no difference in
the likelihood or duration of biochemical response be-
tween groups following TACE.
Overall survival for the NCLM group was significantly
longer than patients with CLM (Figure 1). Those in
the NCLM cohort had a median overall survival of
87.1 months with 59% alive at 5 years versus 45.6 months
and 36% at 5 years in the CLM cohort. When comparing
the presence of CLM with other factors related to pa-
tient survival, including demographics, details of primary
disease, and extent of metastatic disease (Table 3), the
Table 2 Outcomes following transarterial chemoembolization for metastatic neuroendocrine tumors
Variables Caudate lobe metastases (n = 45) Number of caudate lobe
metastases (n = 41)
P value
Median length of stay in days (range) 5.9 (1 to 27) 4.7 (1 to 17) 0.23
Radiographic responsea 37/45 (82.2%) 34/41 (82.9%) .84
Mean duration of radiographic response in months (range) 14.5 (3 to 61) 12.9 (2 to 71) 0.41
Symptom responseb 29/45 (64.4%) 23/41 (56.1%) .51
Median duration of symptomatic response in weeks (range) 12 (2 to 43) 12.5 (2 to 73) 0.30
Biochemical responsec 40/41 (97.6%) 32/36 (88.9%) 0.18*
Median duration of biochemical response in weeks (range) 13 (1.5 to 53) 17.4 (2.1 to 37.8) 0.91
Percentages are calculated based upon the number of patients with complete data. aDenominators vary based upon availability of post-TACE data; bdenominators
based upon number of patients with carcinoid syndrome prior to TACE; cdenominators vary based upon availability of pancreastatin levels.*Fisher’s exact
probability test.
Figure 1 Overall survival curve in patients with (CLM) and with no (NCLM) caudate lobe metastases from neuroendocrine tumors. Kaplan-Meier
curves with log-rank test were performed to compare survival between the cohort of patients with caudate liver metastases (CLM) versus those
without such lesions (NCLM). Patients with liver metastases, but sparing of the caudate lobe, had significantly improved survival compared to
those with caudate lobe lesions (87.1 vs. 45.6 months, P = 0.031).
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presence of CLM was not an independent predictor of
survival. In patients with caudate lesions whose disease
elsewhere in the liver responded to TACE, failure of re-
sponse in the caudate lobe yielded similar overall median
survivals to those who had responsive caudate lesions
(29 vs. 39 months; P = NS).
Discussion
Between 50% and 75% of patients with neuroendocrine
tumors develop metastatic lesions in the liver, and these
lesions are rarely amenable to curative resection. Mor-
bidity in these patients arises from liver symptomatology
resulting in a significant decrease in quality of life [13].
Liver-directed therapies such as TACE have been suc-
cessful at prolongation of life and improving quality al-
beit in the name of palliation [14]. We identified a
subgroup in which metastases also occurred in the caud-
ate lobe, finding that these lesions are often harbingers
for aggressive pathology as patients with CLM have re-
duced median overall survival. Of note, when compared
to other patient factors, the presence of CLM was not a
significant predictor of survival by multivariate analysis.
To our knowledge, no literature to date has described
the impact of metastatic neuroendocrine tumor to the
caudate lobe.
At our institution, caudate lobe metastases were iden-
tified in 52% of patients who presented for TACE. While
the incidence of CLM in NET has not been described
previously, it is clearly more frequent than other
histologic tumor types where a much lower incidence of
CLM has been reported, ranging from only 4% to 8% of
patients [6-8]. A single institution’s experience with 150
patients showed that the most common indication to
undergo caudate hepatectomy was for metastatic colo-
rectal cancer, followed by cholangiocarcinoma and hepa-
tocellular carcinoma [6]. The survival and oncological
outcomes after isolated caudate lobe resection or in com-
bination with a larger hepatic resection for metastasis from
colorectal cancer are similar to those seen in patients with-
out caudate lobe metastases. Long-term survival is com-
parable to metastases elsewhere in the liver; provided
principles of hepatic surgery are followed [8].
In our study, we investigated all patients who under-
went TACE and had caudate lobe metastases. Patients
were included in the CLM group if they had radio-
graphic evidence (CT or MRI) of caudate lobe involve-
ment regardless of the size of the lesion. Patients with
CLM tended to have a greater tumor burden and were
less likely to have had resection of the primary when
compared to NCLM patients. No significant differences
existed when comparing symptomatology, specifically
with respect to carcinoid-related complaints. This is im-
portant to recognize because the presence of carcinoid
syndrome has been shown to be predictive of better out-
come after liver-directed therapies [15-19].
TACE for metastatic neuroendocrine tumor is a safe
procedure but still associated with complications. In our
study, patients undergoing this procedure had a 10%
complication rate with a 2% mortality rate. Post-TACE
events such as the classic TACE syndrome (right upper
quadrant pain, nausea, vomiting, fatigue, transient rise
in liver transaminases, and fevers) are common and
were not considered complications [19,20]. The two
peri-procedural deaths in our study were related to
acute liver failure leading to multisystem organ failure.
Each of these patients had undergone whole liver che-
moembolization early in our experience and had large
tumor burden. Since these events, our practice has
moved to using staged lobar embolizations in order to
reduce liver-related complications.
The majority of patients with carcinoid syndrome ex-
perienced symptom improvement after TACE regardless
of caudate lobe involvement. This was assessed at each
clinic by way of a complete history and physical examin-
ation. In addition, any increase in octreotide dosage or
report of new or worsening symptoms, no matter how
minor, was interpreted as a sign of progressive disease.
This most likely underestimates the real durability of
symptom response after TACE, but it is the most objective
criteria to assess progression of disease in this retrospect-
ive study.
The biochemical response to TACE was evaluated by
the use of pancreastatin as a marker. Pancreastatin is a
Table 3 Predictors of overall survival after transarterial
chemoembolization in patients with liver metastases
from neuroendocrine tumors
Patient factor Univariate
analysis
Multivariate
analysis
(P value) (P value)
Presence of caudate metastases 0.031
Age over 50 <0.001 0.004
Gender 0.329
Race 0.170
Comorbidities 0.363
Number of liver segments
involved
0.001
Percent of liver involved <0.001 0.003
Primary resected <0.001 <0.001
Pancreatic primary <0.001
Tumor grade 0.422
Presence of lymph node
metastases
0.589
Functional tumor 0.047
Presence of extrahepatic
disease
0.004
Shirley et al. World Journal of Surgical Oncology  (2015) 13:167 Page 5 of 7
split product of chromogranin A and has been shown to
be a sensitive marker in neuroendocrine tumors [21,22].
We have shown that a greater than 20% decrease in pan-
creastatin correlates with improved outcome after TACE,
including improved survival [12]. Using the same parame-
ters, we found similar proportion of patients achieving this
threshold in both groups indicating that overall reduction
in viable tumor burden was accomplished regardless of
the response in the caudate.
Radiographic response was assessed by comparison of
pre-TACE CT scans and/or MRIs to post-TACE imaging.
RECIST is not well suited for regional therapy because
RECIST relies on clear measurement of target lesions
and assumes that changes in these target lesions are re-
flective of changes in all lesions within the entire organ.
Although this method is beneficial when comparing effi-
cacy of systemic therapies, it has inherent flaws when
comparing embolic or particle therapy where tumors
may receive varying amounts of drug. It is unclear if
RECIST criteria should be applied to unilobar TACE,
where tumors often regress on the treated side but pro-
gress in the non-treated lobe. Even less clear is how to
assess lesions that have developed calcifications or ne-
crosis after treatment with TACE but have remained the
same diameter. For these reasons, we decided to utilize
the radiologist’s interpretation, which usually incorpo-
rated RECIST, to simply classify tumors as regressive,
stable, or progressive [11,23]. Radiographic stabilization
or improvement of disease was seen in 82% of patients.
However, on review of the post-TACE imaging, response
specifically in the caudate was uncommon (15.5%) irre-
spective of the response elsewhere in the liver. This lack
of response could be explained by alterations in arterial
anatomy of the caudate lobe compared to the other
lobes of the liver.
There are several limitations to the current study.
Firstly, it is a retrospective review and as such is suscep-
tible to biases inherent to such a study. We reviewed
data at our institution alone. We use TACE as our re-
gional therapy of choice for NET metastases to the liver,
using similar techniques for chemoembolization each
time. Although it is possible differing administration of
chemoembolic materials may impact outcomes, our
technique is the standard for this therapy. It is also pos-
sible that other regional therapies, such as bland
embolization or radioembolization, may vary in the im-
pact on caudate lesions. Such comparisons would be be-
yond the scope of this study. Although all deaths were
attributed to disease, our database did not parse out
exact cause in order to differentiate those who suc-
cumbed to liver failure versus other causes. Although
several recent studies [24-26] have shown the import-
ance of extent of primary tumor and presence of peri-
toneal carcinomatosis in determining outcome in small
bowel NET, our database did not collect this data and,
as such, could not be used to compare between groups.
In sum, this study provides insight into the impact of
TACE, specifically, in the treatment of caudate NET
metastases.
Conclusions
Although patients with or without caudate metastases
have similar radiographic, symptomatic, and biochemical
responses to TACE, the lesions in the caudate lobe
themselves respond poorly to TACE compared to lesions
in other lobes of the liver. Additionally, overall survival
after TACE was negatively impacted by the presence of a
caudate lesion. It is unlikely that the mere presence of
CLM affects survival given that when disease elsewhere
in the liver responded to TACE, failure of response in
the caudate lobe yielded similar overall survival to those
who had responsive caudate lesions. Instead, CLM may
reflect greater tumor burden. We show that these lesions
do not respond well to TACE in spite of typically good
response in the remainder of the liver. Given the long
duration of patient survival, caudate lesions may become
quite large, symptomatic, or encroach upon portal struc-
tures. Given the inability of TACE to control growth,
these lesions may best be treated with resection in order
to palliate these effects.
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